AR and prostate carcinoma: This dramatic decline in survival highlights the severity of disease progression, especially during the metastatic castration-resistant prostate cancer (mCRPC) phase, where tumors may transform into an androgen receptor (AR)-negative or neuroendocrine (NE) phenotype, complicating treatment and promoting resistance.